

**Date: October 23, 2024**

To,  
Listing Department  
Bombay Stock Exchange  
**25<sup>th</sup> Floor. P.J.Towers, Dalal Street,  
Fort, Mumbai - 400 001**

Dear Sir/ Madam,

Subject: **Intimation under Regulation 51(2) read with Schedule III, Part B of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

**Scrip Code: 975645, ISIN:1NE013P07028**

Pursuant to Regulation 51(2) read with Schedule III, Part B of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, (herein referred as LODR) we inform you that the Board of directors in its meeting held today, i.e. October 23, 2024, which concluded at 07:15 pm (IST), inter alia approved the following items;

- i) Approval of the unaudited financial results and to take note of the Limited Review Report for the quarter ended September 30, 2024.
- ii) Appointment of Mr. Jason T Spacek, as the Chief Business Officer (CBO) of the Company.
- iii) Consider and approve revision of Management Committee charter of the Company.
- iv) Consider and approve issuance of upto 62,85,746 equity shares of face value of INR 1/- each and premium of INR. 1,275/- aggregating up to INR 8,010,611,884/- (the "Issue")
- v) Consider and approve the Corporate Office address of the Company.

The above information is also available on the website of the Company i.e. <https://www.onesourcecdmo.com/press-releases/>. You are requested to kindly take the same on record.

For and on behalf of  
**OneSource Specialty Pharma Limited**

A TRISHA Digitally signed by A  
TRISHA  
Date: 2024.10.23 19:15:10  
+05'30'

**Trisha A**  
Company Secretary and Compliance Officer  
Membership Number: A47635

## # (Contd..)

### Brief Profile: Jason T Spacek

Jason is a highly accomplished commercial leader with extensive experience in leading Sales teams, driving business growth, and managing P&Ls in some of the world's largest CDMOs including **Catalent, Lonza and Alcami**. He has a proven track record of improving sales team performance, optimizing operational excellence, and identifying market opportunities to deliver consistent growth.

His last role was of Vice President, Business Development - Cell & Gene Therapy at Catalent, having previously led the Biologics and Drug Product verticals over four years in increasingly senior commercial roles. His leadership roles at Lonza and Alcami spanned across biologics and small molecules.

Jason has successfully led teams across strategic business planning, sales performance, portfolio management, and customer relationship management.

He will continue to be based out of North Carolina.

**Education:** Jason holds a Master of Science in Cell and Molecular Biology from Towson University and a Bachelor of Science in Microbiology from the University of Maryland.

His expertise in contract negotiation, strategic marketing, and commercial leadership has contributed to his success in the life sciences industry.

